CD274 and non-small cell lung carcinoma: Recent findings from this trial indicated that the combination of nivolumab and ipilimumab enhanced OS for those patients with PD-L1 expression levels of more than 1%, suggesting that the ICI two-drug combination could be considered as a first-line therapy for NSCLC.